Samsung Biologics Sets New Standards in Carbon Transparency
Samsung Biologics has achieved a significant milestone in its sustainability journey by validating its Product Carbon Footprint (PCF) system according to globally recognized standards. The validation process has been conducted by Det Norske Veritas (DNV), an independent third-party assurance provider, confirming that the company's carbon accounting practices align with ISO and PAS standards.
Strengthening Sustainability Credibility
This validation marks a vital step for Samsung Biologics in reinforcing its commitment to credible carbon accounting. The company’s approach is designed to support its net-zero goals, ensuring that clients receive reliable and consistent carbon footprint data. Validation by DNV not only confirms compliance with international standards but also highlights Samsung Biologics’ methodical approach to sustainability in biopharmaceutical manufacturing.
In-Depth Validation Process
During the assessment, DNV meticulously evaluated Samsung Biologics' PCF methodology across various stages, from data input to output. This rigorous process ensures that the assumptions and methods applied are in harmony with globally accepted practices, thereby enhancing the reliability of the carbon footprint data shared with clients and stakeholders.
Enhancing Communication in the Biopharmaceutical Sector
With the validated PCF framework, Samsung Biologics aims to foster clearer communication regarding product-level carbon footprints across the biopharmaceutical value chain. This initiative responds to increasing client expectations and reinforces sustainability considerations that are becoming integral to the industry.
Leadership's Perspective
John Rim, President and CEO of Samsung Biologics, emphasized the importance of achieving independent validation of their PCF system: "This accomplishment reflects the rigorous standards and transparency inherent in the carbon data we provide to our clients. It showcases our unwavering dedication to sustainable operations while ensuring reliable manufacturing processes. In an era where sustainability is shaping industry decisions, this validation paves the way for collaborative efforts with our partners."
Acknowledgment of Sustainability Achievements
Samsung Biologics' sustainability initiatives have recently garnered external recognition. The company has been awarded a Platinum rating from EcoVadis, placing it within the top one percent of global organizations evaluated for their sustainability management practices. This not only acknowledges the company’s systemic efforts but also reflects its leadership in sustainable business practices.
About Samsung Biologics
Samsung Biologics is a prominent contract development and manufacturing organization (CDMO) that provides comprehensive services from late-stage discovery to commercial manufacturing. The company operates a robust biomanufacturing capacity, bolstered by its two Bio Campus sites, and emphasizes advanced technologies for a diverse range of biopharmaceutical modalities, including mRNA therapeutics.
Innovative Manufacturing Practices
The implementation of the ExellenS™ framework across its manufacturing network is a testament to Samsung Biologics' commitment to quality and efficiency. This framework standardizes manufacturing designs and processes, enhancing operational continuity and ensuring rapid production capabilities. This strategic focus empowers the company to deliver high-quality biomedicines while addressing evolving market demands.
Global Presence and Commitment
Samsung Biologics extends its manufacturing and commercial presence across pivotal regions, including Korea, Japan, and the U.S. With dedicated teams in these regions, the company ensures that clients receive personalized support tailored to their specific needs. The company's ongoing investments in innovative capabilities ensure flexibility and responsiveness, allowing it to remain a reliable partner in the biopharmaceutical landscape.
Frequently Asked Questions
What is the significance of the PCF system validation?
The validation confirms that Samsung Biologics' carbon accounting practices adhere to globally recognized standards, enhancing the credibility of its sustainability efforts.
Who conducted the validation of the PCF system?
The validation was performed by Det Norske Veritas (DNV), an independent assurance provider, ensuring that the methodology aligns with international standards.
How does this validation impact clients?
Clients can expect reliable and consistent carbon footprint data, which supports transparency in sustainability reporting and aligns with evolving industry requirements.
What recognition has Samsung Biologics received for its sustainability efforts?
The company has been awarded a Platinum rating from EcoVadis, positioning it among the top one percent of companies globally for sustainability management.
What are the main areas of focus for Samsung Biologics?
Samsung Biologics focuses on delivering high-quality biomedicines while committing to sustainable practices across its manufacturing and operational processes.
